Skip to main content
. 2014 Apr 6;145(3):725–734. doi: 10.1007/s10549-014-2916-8

Table 4.

Best response to first-line treatment for MBC

Best response, n (%) De novo patients (n = 327) Recurrent patients (n = 674)
Complete response 70 (21.4) 105 (15.6)
Partial response/stable disease 201 (61.5) 385 (57.1)
Progressive disease 48 (14.7) 162 (24.0)
No assessment 8 (2.4) 22 (3.3)

Best observed response confirmed by clinical symptoms, physical examination, or radiology